Yoda and truth seeking in medicine: Making sense of the curious case of rhBMP-2

BMJ (Online)

Volumn 347, Issue 7915, 2013, Pages

  Doshi, Peter ^a   Vedula, S Swaroop ^b   Li, Tianjing ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

BONE TRANSPLANTATION; CLINICAL EFFECTIVENESS; DRUG APPROVAL; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; EDITORIAL; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; RISK ASSESSMENT; SPINE FUSION;

ACCESS TO INFORMATION; BONE MORPHOGENETIC PROTEIN 2; BONE TRANSPLANTATION; DRUG INDUSTRY; HUMANS; RECOMBINANT PROTEINS; REVIEW LITERATURE AS TOPIC; SPINAL FUSION; TRANSFORMING GROWTH FACTOR BETA; UNITED STATES;

EID: 84880059735     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f4251     Document Type: Editorial

References (12)

1. Krumholz HM, Ross JS, Gross CP, Emanuel EJ, Hodshon B, Ritchie JD, et al. A historic moment for open science: the Yale University open data access project and Medtronic. Ann Intern Med 2013;158:910-1.
2. Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med 2013;158:890-902.
3. Simmonds MC, Brown JVE, Heirs MK, Higgins JPT, Mannion RJ, Rodgers MA, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med 2013;158:877-89.
4. Kmietowicz Z. First reviews are published that are based on the "totality of the evidence." BMJ 2013;346:f3909. (17 June.)
5. Krumholz HM, Ross JS. A model for dissemination and independent analysis of industry data. JAMA 2011;306:1593-4.
6. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011;11:471-91.
7. Burkus JK, Heim SE, Gornet MF, Zdeblick TA. Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. J Spinal Disord Technol 2003;16:113-22.
8. Medtronic. First-of-its-kind independent review of INFUSE bone graft coordinated by Yale University is complete. 2013. http://newsroom.medtronic.com/ phoenix.zhtml?c=251324& p=irol-newsArticle&ID=1830515&highlight=.
9. Rodgers MA, Brown JVE, Heirs MK, Higgins JPT, Mannion RJ, Simmonds MC, et al. Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion. BMJ 2013;346:f3981.
10. Hammad TA, Pinheiro SP, Neyarapally GA. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations. Clin Trials 2011;8:559-70.
11. Marciniak TA. Cardiovascular events in the RECORD trial. 2010. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218484.pdf.
12. Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ 2013;346:f2865.